Page 7 - Bart De Strooper News Today

An unprecedented study could lead to a more precise diagnosis of Alzheimer's as well as new treatments for the disease. Scientists have discovered an ad

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present research from its robust Alzheimers...

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present research from its robust Alzheimers...

The Centers for Disease Control and Prevention (CDC)Trusted Source describe dementia as a general term for “the impaired ability to remember, think, or

Experts warn of a potential dementia time bomb, with 153million living with the condition worldwide within decades, fuelled by growing and ageing populations, poor diets and a lack of exercise.

Published: Jul 09, 2021 By Brandon May Muna Therapeutics, a private Denmark- and Belgium-based biopharmaceutical company founded in 2020, officially closed a $73 million Series A financing round. The company launches with the new funding to advance its focus on first-in-class small molecule therapies for neurodegenerative diseases. The Series A financing was led by Novo Holdings in conjunction with Sofinnova Partners, DROIA Ventures and LSP Dementia Fund. Additional investors who join...

Visa fine-tuning to create "radically simplified bureaucracy for high-skilled applications", with quicker processes for entrepreneurs, was a research highlight in the UK’s annual budget on Wednesday. But science groups are left perplexed by the missing billions of pounds earmarked for participation in the EU’s Horizon Europe research programme.

04 Mar 2021   |   News UK budget offers a few crumbs for research, but no Horizon Europe money There are tweaks to the talent visa, but science funding ‘notably scarce’, while there’s no mention of how the government will meet the costs of EU science participation Visa fine-tuning to create "radically simplified bureaucracy for high-skilled applications", with quicker processes for entrepreneurs, was a research highlight in the UK’s annual budget on Wednesday. But science groups are ...

06 Feb 2021 A new APP knock-in mouse has hit the scene. Researchers led by Pascal Sanchez, Denali Therapeutics, San Francisco, California, described the details in a paper posted to bioRxiv on January 20. They humanized the Aβ sequence in the mouse APP gene and knocked in three familial Alzheimer’s disease mutations: Swedish, Arctic, and Austrian. TREM2 expression and cytokine concentrations spiked in brain tissue, microglia flocked to plaques, neurites swelled, and tau and neurofilament lig...